Literature DB >> 28935672

The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain.

Darko Bosnakovski1,2, Erik A Toso2, Lynn M Hartweck2, Alessandro Magli3, Heather A Lee2, Eliza R Thompson2, Abhijit Dandapat2, Rita C R Perlingeiro3, Michael Kyba4.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is caused by inappropriate expression of the double homeodomain protein DUX4. DUX4 has bimodal effects, inhibiting myogenic differentiation and blocking MyoD at low levels of expression, and killing myoblasts at high levels. Pax3 and Pax7, which contain related homeodomains, antagonize the cell death phenotype of DUX4 in C2C12 cells, suggesting some type of competitive interaction. Here, we show that the effects of DUX4 on differentiation and MyoD expression require the homeodomains but do not require the C-terminal activation domain of DUX4. We tested the set of equally related homeodomain proteins (Pax6, Pitx2c, OTX1, Rax, Hesx1, MIXL1 and Tbx1) and found that only Pax3 and Pax7 display phenotypic competition. Domain analysis on Pax3 revealed that the Pax3 homeodomain is necessary for phenotypic competition, but is not sufficient, as competition also requires the paired and transcriptional activation domains of Pax3. Remarkably, substitution mutants in which DUX4 homeodomains are replaced by Pax7 homeodomains retain the ability to inhibit differentiation and to induce cytotoxicity.
© 2017. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  DUX4; Facioscapulohumeral muscular dystrophy; Homeodomain; Myogenesis; Pax3; Pax7

Mesh:

Substances:

Year:  2017        PMID: 28935672      PMCID: PMC5702055          DOI: 10.1242/jcs.205427

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  44 in total

1.  Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.

Authors:  Sara T Winokur; Yi-Wen Chen; Peter S Masny; Jorge H Martin; Jeffrey T Ehmsen; Stephen J Tapscott; Silvere M van der Maarel; Yukiko Hayashi; Kevin M Flanigan
Journal:  Hum Mol Genet       Date:  2003-09-30       Impact factor: 6.150

Review 2.  The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions.

Authors:  Margaret Buckingham; Frédéric Relaix
Journal:  Annu Rev Cell Dev Biol       Date:  2007       Impact factor: 13.827

3.  Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers.

Authors:  Fedik Rahimov; Oliver D King; Doris G Leung; Genila M Bibat; Charles P Emerson; Louis M Kunkel; Kathryn R Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

4.  Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD.

Authors:  Yvonne D Krom; Julie Dumonceaux; Kamel Mamchaoui; Bianca den Hamer; Virginie Mariot; Elisa Negroni; Linda N Geng; Nicolas Martin; Rabi Tawil; Stephen J Tapscott; Baziel G M van Engelen; Vincent Mouly; Gillian S Butler-Browne; Silvère M van der Maarel
Journal:  Am J Pathol       Date:  2012-08-04       Impact factor: 4.307

5.  Inducible cassette exchange: a rapid and efficient system enabling conditional gene expression in embryonic stem and primary cells.

Authors:  Michelina Iacovino; Darko Bosnakovski; Holger Fey; Danielle Rux; Gagan Bajwa; Elisabeth Mahen; Ana Mitanoska; Zhaohui Xu; Michael Kyba
Journal:  Stem Cells       Date:  2011-10       Impact factor: 6.277

6.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.

Authors:  Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott
Journal:  Dev Cell       Date:  2011-12-29       Impact factor: 12.270

7.  Direct isolation of satellite cells for skeletal muscle regeneration.

Authors:  Didier Montarras; Jennifer Morgan; Charlotte Collins; Frédéric Relaix; Stéphane Zaffran; Ana Cumano; Terence Partridge; Margaret Buckingham
Journal:  Science       Date:  2005-09-01       Impact factor: 47.728

8.  A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene.

Authors:  Andreas Leidenroth; Jane E Hewitt
Journal:  BMC Evol Biol       Date:  2010-11-26       Impact factor: 3.260

9.  Gene expression during normal and FSHD myogenesis.

Authors:  Koji Tsumagari; Shao-Chi Chang; Michelle Lacey; Carl Baribault; Sridar V Chittur; Janet Sowden; Rabi Tawil; Gregory E Crawford; Melanie Ehrlich
Journal:  BMC Med Genomics       Date:  2011-09-27       Impact factor: 3.063

10.  DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis.

Authors:  Paul Knopp; Yvonne D Krom; Christopher R S Banerji; Maryna Panamarova; Louise A Moyle; Bianca den Hamer; Silvère M van der Maarel; Peter S Zammit
Journal:  J Cell Sci       Date:  2016-10-15       Impact factor: 5.285

View more
  25 in total

Review 1.  FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?

Authors:  Charis L Himeda; Peter L Jones
Journal:  J Pers Med       Date:  2022-05-25

Review 2.  Pioneer factors as master regulators of the epigenome and cell fate.

Authors:  Aurelio Balsalobre; Jacques Drouin
Journal:  Nat Rev Mol Cell Biol       Date:  2022-03-09       Impact factor: 113.915

Review 3.  Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.

Authors:  Amy E Campbell; Andrea E Belleville; Rebecca Resnick; Sean C Shadle; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

Review 4.  Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals.

Authors:  Ceren Hangül; Sibel Berker Karaüzüm; Esra Küpeli Akkol; Devrim Demir-Dora; Zafer Çetin; Eyüp İlker Saygılı; Gökhan Evcili; Eduardo Sobarzo-Sánchez
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

5.  PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.

Authors:  Christopher R S Banerji; Peter S Zammit
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

6.  Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.

Authors:  Ngoc Lu-Nguyen; Alberto Malerba; Shan Herath; George Dickson; Linda Popplewell
Journal:  Hum Mol Genet       Date:  2021-07-09       Impact factor: 6.150

Review 7.  The prospects of targeting DUX4 in facioscapulohumeral muscular dystrophy.

Authors:  Linde F Bouwman; Silvère M van der Maarel; Jessica C de Greef
Journal:  Curr Opin Neurol       Date:  2020-10       Impact factor: 6.283

8.  Functional domains of the FSHD-associated DUX4 protein.

Authors:  Hiroaki Mitsuhashi; Satoshi Ishimaru; Sachiko Homma; Bryant Yu; Yuki Honma; Mary Lou Beermann; Jeffrey Boone Miller
Journal:  Biol Open       Date:  2018-04-26       Impact factor: 2.422

Review 9.  Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.

Authors:  Anna Greco; Remko Goossens; Baziel van Engelen; Silvère M van der Maarel
Journal:  Clin Genet       Date:  2020-03-04       Impact factor: 4.438

Review 10.  p38 MAPKs - roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets.

Authors:  Christopher M Brennan; Charles P Emerson; Jane Owens; Nicolas Christoforou
Journal:  JCI Insight       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.